Role of Jumonji‐C Histone Demethylase in the Development of Hepatocellular Carcinoma

Abstract

Reprogramming in lipid metabolism has received increasing recognition as a hallmark of cancer cells. In cancer cells, large demands of lipids were required to meet excessive synthesis of membranes, energy production and activation of intracellular signaling pathways during cell proliferation. To meet these demands, cancer cells express increased levels of lipogenic enzymes responsible for FAs synthesis, which is a target of crucial transcriptional regulator, sterol regulatory element binding protein 1c (SREBP1c). SREBP1c is a well‐known master transcription factor for de novo lipogenesis and is found frequently increased in many human cancers. However, the molecular mechanisms involved in the regulation of SREBP1c remain incompletely understood. In this study, we uncover the role of jumonji‐C histone demethylase (JHDM) as a repressor of SREBP1c, thereby preventing lipogenesis and proliferation of hepatocellular carcinoma (HCC) cells. JHDM directly interacts with SREBP1c at basic helix‐loop‐helix domain of SREBP1c and plant homeodomain of JHDM, promoting proteasomal degradation of SREBP1c protein. In addition, knockdown of JHDM stimulates mRNA levels of lipogenic enzymes and induces lipogenesis in HCC cells. However, JHDM‐loss‐induced lipogenesis is recovered by SREBP1c knockdown, implying that SREBP1c is crucial for the effects of JHDM toward lipogenesis. In contrast, ectopic expression of JHDM shows protective effects on oleic acid‐induced lipid accumulation in HCC cells. We also found that JHDM knockdown using si‐RNAs promotes mRNA expressions of cell cycle regulators, accompanied with enhanced cell growth, colony formation and spheroid formation. However, the effects of JHDM knockdown which promote HCC proliferation are reversed by knockdown of SREBP1c. In accordance with these data, JHDM overexpression represses cell growth in HCC cells, indicating that JHDM acts as a tumor suppressor by inhibiting SREBP1c‐mediated lipogenesis and cell cycle regulation. Overall, our findings suggest that JHDM serves as a molecular bridge between lipid metabolism and cancer development through regulation of SREBP1c and thus JHDM could be a therapeutic target in defense against HCC.Support or Funding InformationThis work was supported by grants from the National Research Foundation of Korea (2016R1A2B4013377, 2018R1A2B6007241, 2019R1A2C2083886).